Projecting the transition of COVID-19 burden towards the young population

while vaccines are rolled out: a modelling study

Jun Cai[1]*, Juan Yang[1,2,3]*, Xiaowei Deng[1], Cheng Peng[1], Xinhua Chen[1], Qianhui

Wu[1], Hengcong Liu[1], Juanjuan Zhang[1,2,3], Wen Zheng[1], Junyi Zou[1], Zeyao Zhao[1],

Marco Ajelli[4†], Hongjie Yu[1,2,3†]

1. Department of Infectious Diseases, Huashan Hospital, School of Public Health, Fudan

University

2. Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China

3. Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China

4. Laboratory for Computational Epidemiology and Public Health, Department of

Epidemiology and Biostatistics, Indiana University School of Public Health, Bloomington,

IN, USA

*These authors contributed equally to this work.

[†]These authors are joint senior authors contributed equally to this work.

Corresponding authors: Hongjie Yu, Shanghai Institute of Infectious Disease and

Biosecurity, School of Public Health, Fudan University, Shanghai 200032, China

E-mail: yhj@fudan.edu.cn

Word count (main text): 3,365

Word count (abstract): 265

Abstract

Objectives. SARS-CoV-2 infection causes most cases of severe illness and fatality in older age groups. In China, over 99% of individuals aged ≥12 years have been fully vaccinated against COVID-19 (albeit with vaccines developed against historical lineages), while 65.0% children aged 3–11 years have been vaccinated their first doses (as of November 12, 2021). Here, we aimed to assess whether, in this vaccination landscape, the importation of Delta variant infections could shift the COVID-19 burden from adults to children.

Methods. We developed an age-structured susceptible-infectious-removed model of SARS-CoV-2 transmission dynamics to simulate epidemics triggered by the importation of Delta variant infections and project the age-specific incidence of SARS-CoV-2 infections, cases, hospitalisations, intensive care unit (ICU) admissions, and deaths.

Results. In the context of the vaccination programme targeting individuals aged ≥12 years (as it was the case until mid-October 2021), and in the absence of non-pharmaceutical interventions, the importation of Delta variant infections could have led to widespread transmission and substantial disease burden in mainland China, even with vaccination coverage as high as 97% across the eligible age groups. Extending the vaccination roll-out to include children aged 3–11 years (as it was the case since the end of October 2021) is estimated to dramatically decrease the burden of symptomatic infections and hospitalisations within this age group (54% and 81%, respectively, when considering a vaccination coverage of 99%), but would have a low impact on protecting infants (aged 0–2 years).

Conclusions. Our findings highlight the importance of including children among the target population and the need to strengthen vaccination efforts by increasing vaccine effectiveness.

Introduction

The coronavirus disease 2019 (COVID-19) pandemic is still raging worldwide. The highly contagious Delta variant (B.1.617.2) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become the dominant strain across the world[1,2]. The global circulation of the Delta variant has led to a resurgence of COVID-19 cases worldwide, including in areas with high vaccination coverage[3,4].

A clear positive correlation has been shown between severe illness and fatality from SARS-CoV-2 infection and age[5-7]. COVID-19 vaccines are highly efficacious in preventing severe illness[8-10]. Due to individual choices and age-prioritized vaccination strategies adopted by most countries[11], vaccine coverage tends to be higher in older adults[12,13]. However, since the summer of 2021, while the Delta variant continued its spread, the number of COVID-19 cases and hospitalisations have trended upwards in many countries with an increasing fraction of children and adolescents[14-17].

China has been able to avoid the widespread local transmission of SARS-CoV-2 since April 2020[18]. However, the importations of Delta variant infections have caused several local outbreaks, the largest of which occurred in Nanjing city and led to 1,162 reported cases and spilled to 38 other cities[19]. Similar to what was observed in other countries, the Delta surge started in September 2021 in Putian city has been characterized by a high proportion (77/226) of infections in children younger than 12 years[20].

In China, two inactivated COVID-19 vaccines have already obtained emergency use approval for administration in individuals aged ≥3 years. No vaccine has yet received approval for use in children aged ≤2 years. To prevent the spread of infection in younger age groups, China extended the vaccination programme to include adolescents aged 12–17 years in July 2021, then to include children aged 3-11 years around the end of October 2021 (Figure S2). As of November 12, 2021, 2.24 billion

and 84.395 million doses were administered to 12+ years and 3–11 years group,

respectively, corresponding to 95% and 32.5% of these two target populations[21].

The vaccines used in mainland China were developed using historical SARS-CoV-2

lineages and have proven to be highly effective in protecting against severe illness

caused by the Delta variant[22-24]. However, their effectiveness in preventing infection

appears to be reduced[25]. Moreover, vaccination coverage is highly skewed towards

older age groups. It is thus legit to ask whether the spread of Delta variant infections

and lack of vaccination in younger age groups could shift the COVID-19 burden

towards younger age groups and how this can affect the return to normal. To fill this

gap, we developed an age-structured SARS-CoV-2 transmission model to project age-

specific epidemiological outcomes, should an epidemic start to unfold. In particular,

the model is used to forward simulate alternative vaccination strategies and allows

tracking the number of infections, cases, hospitalisations, intensive care unit (ICU)

admissions, and deaths by age.

Methods

SARS-CoV-2 transmission and vaccination model

We developed an age-structured (16 age groups, Table S2) stochastic compartmental

susceptible-infectious-removed (SIR) model to simulate the transmission of SARS-

CoV-2 (Delta variant) and assess the health impact of age-targeted vaccination

campaigns (Figure S1). Detailed information about the model and adopted parameters

are described in Sec. 1.1 of Supplementary Materials and Methods. A summary is

presented here.

The model is calibrated to represent the Chinese population and considers the age-

mixing patterns quantified prior to the COVID-19 pandemic[26]. Based on contact

tracing data in the Hunan province of China[27], children aged under 15 years were

found to have a lower susceptibility to SARS-CoV-2 infection than other age groups,

which was confirmed by several independent studies[28] (Table S1). A sensitivity

analysis considering homogeneous susceptibility across age groups is presented in

Figure S3. As of November 2021, virtually the entire population of China remains

susceptible to SARS-CoV-2 after containment of the first epidemic wave of COVID-

19[29,30], the model is initialized with a fully susceptible population. Simulations were

seeded with 40 imported infections[31] on December 1, 2021 and run forward for 1 year.

As sensitivity analyses, we consider also 10 and 20 seeds (Table S1). We considered a

basic reproductive number $R_0 = 6$ for the Delta variant[32-34]. It is still unclear whether

the Delta variant has a shorter generation time than the original lineage, with studies

reporting opposite results: an analysis conducted in Singapore found no significant

difference[35], while a study conducted in UK and one in China estimated a shorter

duration than for historical lineages[36,37]. Given this non-conclusive evidence, in the

baseline analysis we set the average generation time of the Delta variant to be 7 days,

in line with estimates for the original lineages[38]. We then considered a shorter

generation time of 4.6 days[39] in a sensitivity analysis (Table S1).

Vaccination strategy and vaccine effectiveness

We considered two vaccination strategies: (1) vaccination of individuals aged ≥12

years (here referred to as the "adults+adolescents" vaccination strategy), in agreement

with the vaccination programme in place in China until mid-October 2021; (2) as in

strategy (1), but the target population was extended to include children aged 3–11

years, as it was the case in China starting from October 28, 2021–this strategy is

referred to here as the "adults+adolescents+children" vaccination strategy. We

consider that susceptible individuals only are eligible for vaccination, mimicking the

programme implemented in China. Booster doses are not considered in this study.

Moreover, we accounted for individuals with contraindications against vaccination

and pregnant women as they were excluded from the Chinese vaccination programme

(Table S2)[39]. We simulated the daily distribution of vaccine doses according to the

observed and projected vaccination capacity (see Sec. 1.2 in Supplementary Materials

 for details).

We considered a two-dose vaccine with a 21-day interval between doses. Fourteen days after the second dose, the vaccine efficacy in protecting against an infection caused by the Delta variant was set at 54.3%[39]. The considered different vaccine effectiveness (VE) against each of the following clinical endpoints: infection, symptomatic disease, hospitalisation, ICU admission, and death (see Table 1). We further explored a range of higher VE values for sensitivity analyses (Figure S9). We considered VE to be homogeneous across age groups[40-42]. We considered a "leaky" vaccine in which all vaccinated individuals are exposed to a lower risk of infection, which is 1-VE times that of non-vaccinated individuals[43]. We assumed that both the vaccine and natural infection confer protection for longer than the study period (i.e., 1 year)[44].

Model of COVID-19 burden

The number of infections was produced by the transmission model previously described. To estimate COVID-19 burden, we rescaled the number of infections to obtain estimates of the cumulative incidence of symptomatic cases, hospitalisations, ICU admissions, and deaths under different vaccination strategies using the corresponding age-specific risks estimated for historical lineages and then corrected for the increased severity of the Delta variant (Table 1 – details reported in Sec. 1.3 in Supplementary Materials and Methods). Briefly, by integrating studies conducted in China[45], Scotland[46], Canada[47], and England[48,49], we estimated that the increased risk associated with the Delta variant was 1.78 (0.92–3.13) for hospitalisation, 2.17 (0.95–4.59) for ICU admission, and 1.33 (0.54–2.31) for death as compared to the original lineage, respectively (Table 1). We also assumed that the age-specific probability of developing symptoms upon Delta infection is similar to that of the historical lineage. This choice was inspired by the finding that no significant difference was found for the Alpha variant as compared to historical lineages[50]. To compare the severity of

disease across different age groups, we calculated the rate ratios as the incidence rate

per age group dividing the overall incidence rate for each health outcome under

different vaccination strategies.

Data analysis

For each scenario, 200 stochastic simulations were performed. The outcomes of these

simulations determined the distribution of the cumulative number of symptomatic

infections, hospitalisations, ICU admissions, and deaths by age. We defined 95%

credible intervals as quantiles of the estimated distributions of 0.025 and 0.975.

Results

Baseline scenario

The baseline scenario assumes that 40 individuals infected with the Delta variant were introduced in the population on December 1, 2021, and the basic reproduction number R_0 was 6 in the absence of interventions and immunity[32-34]. Given vaccination rates data, we project that the "adults+adolescents" vaccination strategy could reach a 97% coverage of the target population (83% of the total population) by November 12, 2021 (Figure 1A).

Model simulations suggest that the importation of Delta variant infections in December 2021 could have the potential to generate a major epidemic wave in the absence of non-pharmaceutical interventions (NPIs). Such an epidemic is estimated to cause 1,693 (95% CI, 1,596–1,738) symptomatic infections, 827 (95% CI, 757–856) hospitalisations, 39 (95% CI, 37–41) ICU admissions, and 38 (95% CI, 35–39) deaths per 10,000 individuals over 1 year (Figures 1C and 2). These figures correspond to 10–22 fold the disease burden of the initial epidemic in Wuhan, China[6]. Under the adopted vaccination programme, 13% of symptomatic infections and 30% of hospitalisations were estimated to occur in children younger than 12 years (Figure S8), who were ineligible for COVID-19 vaccination until mid-October 2021.

Two inactivated COVID-19 vaccines have been licensed for use in children aged 3–17 years[51,52]. However, vaccination has not been implemented among children aged 3–11 years until the end of October 2021. Here, we simulate a scenario where the vaccine is offered to children aged 3–11 years (representing 11.0% of the population) from October 28, 2021 (i.e., the "adults+adolescents+children" vaccination strategy). It is projected that about 41.3% of children aged 3–11 years are fully vaccinated at the (assumed) time of importation of the Delta variant on December 1, 2021 (Figure 1). As compared to the "adults+adolescents" vaccination strategy, this alternative strategy is estimated to reduce the incidence of symptomatic cases, hospitalisations, ICU

admissions, and deaths by 6% (95% CI, 3–12%), 20% (95% CI, 17–27%), 8% (95% CI, 4–15%), and 5% (95% CI, 1–13%), respectively (Figure 2). Despite the beneficial mitigation effect of this strategy, extending vaccination to children is estimated not to be enough to suppress viral circulation. Indeed, 5.1 million deaths (95% CI, 4.7–5.4) (approximately 0.4% of the Chinese population) are projected under this vaccination programme, should NPIs not be implemented (Figure S8).

We used the model to simulate a counterfactual scenario to estimate what would have happened if a vaccination programme had not been implemented. Compared with a no vaccination scenario, the "adults+adolescents" vaccination strategy led to a 47% and 54% increase in the rate ratios of symptomatic infections in children aged 0–2 and 3–11 years, respectively. We recall that the rate ratio is defined as the incidence rate per age group divided by the overall incidence rate[53]. A higher increase is observed in the rate ratios of hospitalisation for these two population groups: 178% and 191% for children aged 0–2 and 3–11 years, respectively. At the same time, the rate ratios in adults aged ≥60 years is estimated to decrease by 25%. Similar patterns are observed in the rate ratios of ICU admissions and deaths (Figure 3). Extending the vaccination to children aged 3–11 years is projected to dramatically decrease the burden of symptomatic infections and hospitalisations within the same age group by 54% and 81%, respectively (Figure S8). However, due to the strong age-assortativity of contact patterns of this age group (i.e., individuals aged 3–11 years primarily mix with other individuals of the same age) (Figure S4A), extending the vaccination to children does not strongly impact the COVID-19 burden in other age groups (Figure S8). No evident effect is projected on the 0–2-year age group (Figures 3 and S8).

Under either the "adults+adolescents" or "adults+adolescents+children" vaccination strategies, the mean incidence of symptomatic cases among unvaccinated individuals is estimated to be 1.5–2.0 fold that of vaccinated individuals, with larger differences observed in terms of the incidence of severe clinical outcomes (3.4–5.0 fold for

hospitalisation, 2.9–8.9 fold for ICU admission, and 3.4–8.9 fold for death) (Figure

2).

Improving VE in the absence/presence of NPIs

In our model, VE in preventing ICU admissions and deaths caused by a Delta variant

infection was set at 93%, based on real-world VE studies in Guangdong and Jiangsu,

China (Table 1)[22-24]. Should the VE against the infection of the Delta variant be

increased to >83% from 54.3% used in the baseline[39], the

"adults+adolescents+children" vaccination strategy is estimated to reduce the number

of deaths by 99% even in the absence of any NPIs, leading to <34,000 deaths over 1

year, similar to the annual excess respiratory disease deaths associated with influenza

in China[54] (Figure S9).

We leveraged the developed model to explore the impact of implementing different

levels of NPIs on the COVID-19 burden while the "adults+adolescents+children"

vaccination strategy is in place and considering different levels of VE against

infection. When VE against infection is set at 54.3% (baseline scenario), stringent

NPIs capable of maintaining the net reproduction number R_e<2.5 are needed, in

combination with the vaccination programme, to reduce the yearly COVID-19 death

toll to a level similar to that of seasonal influenza[54] (<44,000 deaths). Should a new

vaccine with higher (>75%) VE against the infection be adopted, NPIs could be

relaxed. Moderate NPIs able to keep R_e<4.4 in combination with the vaccination

programme is estimated to be sufficient to decrease the annual number of deaths to

less than 60,000 (Figure S9).

Sensitivity analyses

In the baseline analysis, age-varying susceptibility to SARS-CoV-2 infection was

considered. That is, using adults aged 15–64 years as a reference group, children have

a 42% lower risk of infection than adults (Table S1)[27]. No estimates are available for

susceptibility to Delta variant infections by age. As such, we performed an analysis

assuming the same susceptibility to infection across all age groups. The obtained

results are consistent with those obtained in the baseline analysis, with average

variations lower than 12% (Figure S3).

Another feature able to shape the epidemiology of COVID-19 is the contact pattern of

the population. In the baseline analysis, we used pre-pandemic mixing patterns to

represent a situation close to the objective of returning to a pre-COVID-19 pandemic

lifestyle[26] (Figure S4A). However, whether mixing patterns will ever return to be the

same after the pandemic remains to be seen. As such, we tested the robustness of our

findings by considering an alternative contact matrix estimated in Shanghai, China,

right after the end of the lockdown in March 2020[55] (Figure S4B). The obtained

results are consistent with those obtained with the pre-pandemic contact matrix, with

mean variations in the estimated burden lower than 6% (Figure S5).

We further tested the robustness of our findings by assuming a shorter generation time

of 4.6 days and less (10 and 20) imported seed infections. The obtained disease

burden is consistent with those obtained in the baseline analysis across age groups and

vaccination strategies (Figures S6 and S7).

Discussion

Our modelling study indicates that, under a vaccination programme targeting

individuals aged ≥12 years, symptomatic SARS-CoV-2 infections and hospitalisation

would shift towards children and young adolescents in the case of a new COVID-19

wave caused by the Delta variant. These modelling results obtained for China are

backed up by empirical evidence from other countries, where an upsurge of COVID-

19 cases and hospitalisations among children and adolescents has been reported since

the summer of 2021[14,15,53]. Evidence of this epidemiological shift towards children

and adolescents comes from the analyses of local outbreaks in Putian city, China, in

September 2021, where 34.1% of the reported cases occurred in those aged 0–11

years[20].

The numbers depicted by the model are related to the relatively low vaccine efficacy

against Delta variant infection of the vaccines in use in China (54.3%[39]) as of

November 2021. Model projections show that, in the absence of NPIs, even when

97% of the population aged $\geqslant$12 years is fully vaccinated, the importation of Delta

variant infections could lead to a new COVID-19 wave and substantial health burden.

In particular, the estimated number of deaths over 1 year was 38 per 10,000

individuals as compared, for instance, with 3.6 deaths per 10,000 individuals in the

first epidemic wave in Wuhan in early 2020[6]. Extending vaccination to children could

mitigate the number of symptomatic cases and severe outcomes but would not be

enough to suppress transmission. Relying on NPIs such as border control screenings,

border quarantine, isolation, and mask wearing remains key in this phase of

widespread circulation of highly transmissible SARS-CoV-2 variants across the globe.

This finding is consistent with studies in France, the UK, and the US where, despite

the distribution of more effective vaccines (e.g., mRNA vaccines and adenoviral

vector vaccines), the transmission is far from being suppressed as of November

2021[56-58].

To return to normal (i.e., no NPIs), the combination of high vaccine coverage,

including children and adolescents, and a highly efficacious vaccine that prevents

infection appear to be key to reducing COVID-19 burden to levels closer to those of

seasonal influenza. To reach this target, in addition to extending vaccination to

children aged 3–11 years as what is being implemented in China since the end of

October 2021, our modelling results suggest that vaccine efficacy against the infection

would need to be increased to >83%, slightly higher than the efficacy estimated for

the mRNA-1273 (Moderna) vaccine[10]. China is currently attempting to develop

mRNA vaccines[59], vaccines that specifically target the Delta variant[60], multi-valent

vaccines, and universal vaccines[61-63]. However, whether such vaccines will become available in the short term is unknown. Moreover, the waning of vaccine-induced immunity may also worsen the situation[57,64-66]. For this reason, several countries recommend booster shots, at least for certain high-risk groups[67,68]. The debate on whether to prioritize the administration of booster doses to older age groups or extend the vaccination programme to those aged 3–11 years merits further modelling investigations. Currently, the best way to protect infants (aged 0–2 years) appears to be by vaccinating their contacts, such as family members.

Although the inactivated vaccines in use in China as of November 2021 show a relatively low effectiveness against mild and moderate disease caused by Delta variant infection, they appear to be highly effective against severe outcomes[8,22-24]. In the context of a constantly changing virus and the evolving epidemiology of the pandemic, it is of great importance to continue to ramp up efforts to increase vaccination coverage by using currently available vaccines. Promoting equitable access to COVID-19 vaccines is critical to decreasing viral circulation and the likelihood of the emergence of new variants of concern.

Limitations

Our findings should be interpreted by considering the following limitations. First, we assumed that vaccine protection lasted longer than the time of our simulations (1 year). Recent immunological studies have shown that the neutralising antibody titres of inactivated vaccines decline to a low level at 6 months after the second vaccine dose[64,65], which may indicate waning of vaccine efficacy. However, the correlation with protection from SARS-CoV-2 infection has yet to be proven. Second, we estimated the disease burden potentially caused by the importation of Delta variant infections in the absence or presence of NPIs. The impact of NPIs has been modelled through a simple reduction in transmissibility occurring homogenously with age. We still lack evidence regarding whether this is the case or whether NPIs lead to age-

related effects. Moreover, our analysis is not suited to pinpoint which NPIs need to be

performed to reach the considered levels of transmission reduction. Further studies

exploring this direction are required.

Conclusions and Public Health Implications

Although vaccination is key to dramatically reducing severe outcomes of SARS-CoV-

2 infections and the overall burden of the COVID-19 pandemic, in the absence of

NPIs, the importation of Delta variant infections could lead to widespread

transmission and substantial disease burden in mainland China, even with vaccination

coverage as high as 97% of those aged ≥12 years (VE=54.1% in preventing the

infection). Moreover, vaccination programmes targeting individuals aged ≥12 years

only can potentially shift the COVID-19 burden towards younger ages. Extending

vaccination to children aged 3-11 years would mitigate the disease burden within this

age group, but would not be enough to suppress transmission.

Our findings highlight the need to strengthen vaccination efforts by simultaneously

extending the target age groups of the vaccination campaign, and elevating VE via

booster vaccination and/or developing new highly efficacious vaccines in China.

Contributors

H.Y. conceived, designed, and supervised the study. J.C. and X.D. developed the model. J.C., J.Y., X.D., X.C., Q.W., H.L., J.J.Z., W.Z., J.Y.Z., and Z.Z. collected the data. J.C., J.Y., X.D., M.A., and H.Y. interpreted the results. J.C., X.D., and C.P. prepared the tables and figures. J.C. and J.Y. wrote the first draft of the manuscript. M.A. and H.Y. critically revised the content. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Acknowledgments

This study was supported by grants from the Key Program of the National Natural Science Foundation of China (82130093) and the National Institute for Health Research (NIHR) (grant no. 16/137/109) using UK aid from the UK Government to support global health research. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care.

Conflicts of interest

H.Y. received research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang HEC Changjiang Pharmaceutical Company, Shanghai Roche Pharmaceutical Company, and SINOVAC Biotech Ltd. M.A. received research funding from Seqirus. Except for research funding from SINOVAC Biotech Ltd, which is related to the data analysis of clinical trials of immunogenicity and safety of CoronaVac, the others are not related to COVID-19. All the other authors have no competing interests.

Human participant protection

This study collected only publicly available data and did not involve human participants. No institutional review board approval was needed.

Data sharing

399   The data and code that support the findings of this study will be made available on

400   GitHub upon the acceptance of this manuscript.

Tables

Table 1. Parameters regulating the transmissibility, vaccine effectiveness/efficacy, and COVID-19 burden

Parameter description	Estimated value for the Delta variant
Epidemiology	
Basic reproduction number (R_0)	6[32-34]
Vaccine effectiveness/efficacy	
Against infection (%) (ϵ)	54.3[39]
Against symptomatic disease (%) (ϵ^{symp})	69.5 (42.8, 96.3)[22]
Against hospitalisations (%) (ϵ^{hosp})	87.5 (86.7, 88.2)[8] [a]
Against ICU admissions (%) (ϵ^{icu})	93[22-24] [b]
Against deaths (%) (ϵ^{death})	93[22-24]
Disease burden [c]	
Proportion of infections that develop symptoms for the wild-type ($r_{a,WT}^{symp}$)	18.1%, 22.4%, 30.5%, 35.5%, and 64.6% for 0–19, 20–39, 40–59, 60–79, and ≥80 years[7]
Proportion of infections that require hospitalisation for the wild-type ($r_{a,WT}^{hosp}$)	7.24%, 6.54%, 10.16%, 12.00%, and 21.83% separately for 0–19, 20–39, 40–59, 60–79, and ≥80 years[6,7]
Proportion of infections that require ICU for the wild-type ($r_{a,WT}^{icu}$)	0.1014%, 0.2747%, 0.4266%, 0.7617%, 0.8999%, 2.8198%, and 5.1312% separately for 0–19, 20–39, 40–49, 50–59, 60–64, 65–79, and ≥80 years[6,7,69]
Infection fatality ratio for the wild-type ($r_{a,WT}^{death}$)	0.0923%, 0.1456%, 0.7259%, 3.7346%, and 6.7959% separately for 0–19, 20–39, 40–59, 60–79, and ≥80 years[6,7]
Risk ratio of symptomatic infection associated with the Delta variant compared to the wild-type ($\Delta_{WT\rightarrow Delta}^{symp}$)	1[50] [d]
Risk ratio of hospitalisation associated with the Delta variant compared to the wild-type ($\Delta_{WT\rightarrow Delta}^{hosp}$)	2.78 (1.92, 4.13)[46-49]
Risk ratio of ICU admission associated with the Delta variant compared to the wild-type ($\Delta_{WT\rightarrow Delta}^{icu}$)	3.17 (1.95, 5.59)[45,47]
Risk ratio of death associated with the Delta variant compared to the wild-type ($\Delta_{WT\rightarrow Delta}^{death}$)	2.33 (1.54, 3.31)[47]

[a] Although the main variants of concern detected in Chile during the study period from February 2 to May 1, 2021 were the Alpha and Gamma variants, we assume that the effectiveness reported in reference [8] applies to the Delta variant.

[b] Pooling the effectiveness of inactivated COVID-19 vaccines against severe illness caused by the Delta variant estimated in the recent outbreaks of the Delta variant in Guangdong[22,23] and Jiangsu[24], China, we assume conservative effectiveness in preventing serious illness.

[c] The risks of different clinical outcomes associated with the Delta variant are expressed as increased risks compared to the wild-type.

412   [d] Based on the conclusion that no significant change in reported symptoms associated with the Alpha variant

413   compared to wild-type is found in reference[50], we assume that the probability of developing symptoms by age for

414   the Delta variant is the same as the wild-type.

Figure 1. Time series of vaccine coverage and daily incidence of new SARS-CoV-2 Delta variant infections. A Age-specific vaccine coverage over time for the "adults+adolescents" vaccination strategy. The vaccination programme was initiated on November 30, 2020 (as first officially reported in China). The vertical dotted lines represent the (simulated) seeding of the infection (December 1, 2021). The subpanel reports a table showing the age-specific coverage. The line corresponds to the mean value, while the shaded area represents the 95% quantile intervals (CI). **B** As A, but for the "adults+adolescents+children" vaccination strategy. **C** Simulated daily incidence of new SARS-CoV-2 Delta variant infections per 10,000 individuals for the two strategies (mean and 95% CI).

Figure 2. Age profile of projected disease burden caused by an epidemic of imported SARS-CoV-2 Delta variant infections in China. A Cumulative number of symptomatic cases per 10,000 individuals after one simulated year by vaccination strategy (AA = "adults+adolescents" vaccination strategy, AAC = "adults+adolescents+children" vaccination strategy), vaccination status, and age group. The vaccinated group are those individuals who are administrated with two doses. **B** As A, but for the incidence of hospitalisations. **C** As A, but for the incidence of ICU admissions. **D** As A, but for mortality. The horizontal dotted lines in **A**, **B**, and **D** represent the rates of symptomatic cases, hospitalisations, and deaths, respectively, of the first pandemic wave of COVID-19 in Wuhan, China[6].

Figure 3. Rate ratios of symptomatic cases, hospitalisations, ICU admissions, and deaths due to SARS-CoV-2 Delta variant infections in China by age group and vaccination strategy. NV = no vaccination, AA = "adults+adolescents" vaccination strategy, AAC = "adults+adolescents+children" vaccination strategy.

References

1. WHO Team Emergency Respinse. Weekly epidemiological update on COVID-19 - 10 August 2021. 2021; https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---10-august-2021. Accessed 2021-08-12, 2021.

2. CDC. Delta Variant: What We Know About the Science. 2021; https://www.cdc.gov/coronavirus/2019-ncov/variants/delta-variant.html. Accessed 2021-08-20, 2021.

3. WHO. WHO Coronavirus (COVID-19) Dashboard. 2021; https://covid19.who.int/. Accessed 2021-09-07, 2021.

4. Our World in Data. Coronavirus (COVID-19) Vaccinations. 2021; https://covid19.who.int/. Accessed 2021-09-07, 2021.

5. O'Driscoll M, Ribeiro Dos Santos G, Wang L, et al. Age-specific mortality and immunity patterns of SARS-CoV-2. *Nature.* 2021;590(7844):140-145.

6. Yang J, Chen X, Deng X, et al. Disease burden and clinical severity of the first pandemic wave of COVID-19 in Wuhan, China. *Nature Communications.* 2020;11(1):5411.

7. Poletti P, Tirani M, Cereda D, et al. Association of Age With Likelihood of Developing Symptoms and Critical Disease Among Close Contacts Exposed to Patients With Confirmed SARS-CoV-2 Infection in Italy. *JAMA Network Open.* 2021;4(3):e211085-e211085.

8. Jara A, Undurraga EA, González C, et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. *New England Journal of Medicine.* 2021.

9. Chemaitelly H, Yassine HM, Benslimane FM, et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. *Nature Medicine.* 2021.

10. Tang P, Hasan MR, Chemaitelly H, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. *Nature Medicine.* 2021.

11. Noh EB, Nam H-K, Lee H. Which Group Should be Vaccinated First?: A Systematic Review. *Infect Chemother.* 2021;53(2):261-270.

12. CDC. Demographic Characteristics of People Receiving COVID-19 Vaccinations in the United States. 2021; https://covid.cdc.gov/covid-data-tracker/#vaccination-demographic. Accessed 2021-09-07, 2021.

13. UK Health Security Agency. COVID-19 vaccine weekly surveillance reports. 2021; https://www.gov.uk/government/publications/covid-19-vaccine-weekly-surveillance-reports. Accessed 2021-11-18, 2021.

14. Siegel DA. Trends in COVID-19 Cases, Emergency Department Visits, and Hospital Admissions Among Children and Adolescents Aged 0–17 Years—United States, August 2020–August 2021. *MMWR Morbidity and Mortality Weekly Report.* 2021;70.

15. Delahoy MJ. Hospitalizations Associated with COVID-19 Among Children and Adolescents—COVID-NET, 14 States, March 1, 2020–August 14, 2021. *MMWR Morbidity and Mortality Weekly Report.* 2021;70.

16. Office for National Statistics of the UK. Coronavirus (COVID-19) latest insights. 2021; https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19latestinsights/Overview. Accessed 2021-09-17,

487   2021.

488   17.   Israel Ministry of Health. Coronavirus in Israel - general situation dashboard. 2021;
489   https://datadashboard.health.gov.il/COVID-19/general. Accessed 2021-11-10, 2021.

490   18.   National Health Commission. Notification on situation of COVID-19 epidemic in China.
491   2021; http://www.nhc.gov.cn/xcs/yqtb/list_gzbd.shtml. Accessed 2021-09-17, 2021.

492   19.   Lei Z, Kai N, Hongting Z, et al. Eleven COVID-19 Outbreaks with Local Transmissions
493   Caused by the Imported SARS-CoV-2 Delta VOC — China, July–August, 2021. *China CDC*
494   *Weekly.* 2021;3(41):863-868.

495   20.   Li H, Lin H, Chen X, et al. A need of COVID19 vaccination for children aged <12 years:
496   Comparative evidence from the clinical characteristics in patients during a recent Delta
497   surge (B.1.617.2). *medRxiv.* 2021:2021.2011.2005.21265712.

498   21.   The State Council Information Office PRC. Press conference held on situation regarding
499   prevetion   and   control   of   the   COVID-19   epidemic   and   vaccination.   2021;
500   http://www.nhc.gov.cn/xcs/s3574/202109/f89d117481b24572a346c19fde76a396.shtml.
501   Accessed 2021-09-17, 2021.

502   22.   Kang M, Yi Y, Li Y, et al. Effectiveness of Inactivated COVID-19 Vaccines Against COVID-
503   19 Pneumonia and Severe Illness Caused by the B. 1.617. 2 (Delta) Variant: Evidence from
504   an Outbreak in Guangdong, China. *SSRN.* 2021.

505   23.   Li X-n, Huang Y, Wang W, et al. Efficacy of inactivated SARS-CoV-2 vaccines against the
506   Delta variant infection in Guangzhou: A test-negative case-control real-world study.
507   *Emerging Microbes & Infections.* 2021:1-32.

508   24.   Wang J, Huang P, Yi Y, et al. Effectiveness of inactive COVID-19 vaccines against severe
509   illness in B.1.617.2 (Delta) variant-infected patients in Jiangsu, China. *medRxiv.*
510   2021:2021.2009.2002.21263010.

511   25.   Chen X, Wang W, Chen X, et al. Prediction of long-term kinetics of vaccine-elicited
512   neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-
513   2 Delta variant by clinical endpoint. *medRxiv.* 2021:2021.2009.2023.21263715.

514   26.   Zhang J, Klepac P, Read JM, et al. Patterns of human social contact and contact with
515   animals in Shanghai, China. *Scientific Reports.* 2019;9(1):15141.

516   27.   Hu S, Wang W, Wang Y, et al. Infectivity, susceptibility, and risk factors associated with
517   SARS-CoV-2 transmission under intensive contact tracing in Hunan, China. *Nature*
518   *Communications.* 2021;12(1):1533.

519   28.   Viner RM, Mytton OT, Bonell C, et al. Susceptibility to SARS-CoV-2 Infection Among
520   Children and Adolescents Compared With Adults: A Systematic Review and Meta-analysis.
521   *JAMA Pediatrics.* 2021;175(2):143-156.

522   29.   Chen X, Chen Z, Azman AS, et al. Serological evidence of human infection with SARS-
523   CoV-2: a systematic review and meta-analysis. *The Lancet Global Health.* 2021;9(5):e598-
524   e609.

525   30.   Li Z, Guan X, Mao N, et al. Antibody seroprevalence in the epicenter Wuhan, Hubei, and
526   six selected provinces after containment of the first epidemic wave of COVID-19 in China.
527   *The Lancet Regional Health - Western Pacific.* 2021;8:100094.

528   31.   Yang J, Marziano V, Deng X, et al. Despite vaccination, China needs non-pharmaceutical
529   interventions to prevent widespread outbreaks of COVID-19 in 2021. *Nature Human*
530   *Behaviour.* 2021;5(8):1009-1020.

32. Scientific Advisory Group for Emergencies. SPI-M-O: Consensus Statement on COVID-19,
12 May 2021. 2021; https://www.gov.uk/government/publications/spi-m-o-consensus-
statement-on-covid-19-12-may-2021. Accessed 2021-06-11, 2021.

33. Dagpunar J. Interim estimates of increased transmissibility, growth rate, and reproduction
number of the Covid-19 B.1.617.2 variant of concern in the United Kingdom. *medRxiv.*
2021:2021.2006.2003.21258293.

34. Challen R, Dyson L, Overton CE, et al. Early epidemiological signatures of novel SARS-
CoV-2 variants: establishment of B.1.617.2 in England. *medRxiv.*
2021:2021.2006.2005.21258365.

35. Pung R, Mak TM, Kucharski AJ, Lee VJ. Serial intervals in SARS-CoV-2 B.1.617.2 variant
cases. *The Lancet.* 2021.

36. Meng Z, Jianpeng X, Aiping D, et al. Transmission Dynamics of an Outbreak of the COVID-
19 Delta Variant B.1.617.2 — Guangdong Province, China, May–June 2021. *China CDC*
Weekly. 2021;3(27):584-586.

37. Hart WS, Miller E, Andrews NJ, et al. Generation time of the Alpha and Delta SARS-CoV-
2 variants. *medRxiv.* 2021:2021.2010.2021.21265216.

38. Sun K, Wang W, Gao L, et al. Transmission heterogeneities, kinetics, and controllability of
SARS-CoV-2. *Science.* 2020:eabe2424.

39. Liu H, Zhang J, Cai J, et al. Herd immunity induced by COVID-19 vaccination programs
and suppression of epidemics caused by the SARS-CoV-2 Delta variant in China. *medRxiv.*
2021:2021.2007.2023.21261013.

40. Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on
Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. *JAMA.* 2021.

41. Palacios R, Batista AP, Albuquerque CSN, et al. Efficacy and safety of a COVID-19
inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV study. *SSRN.* 2021.

42. Han B, Song Y, Li C, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-
CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind,
randomised, controlled, phase 1/2 clinical trial. *The Lancet Infectious Diseases.* 2021.

43. Halloran ME, Longini IM, Struchiner CJ, Longini IM. *Design and analysis of vaccine studies.*
Vol 18: Springer; 2010.

44. Wang Z, Muecksch F, Schaefer-Babajew D, et al. Naturally enhanced neutralizing breadth
against SARS-CoV-2 one year after infection. *Nature.* 2021;595(7867):426-431.

45. Wang Y, Chen R, Hu F, et al. Transmission, viral kinetics and clinical characteristics of the
emergent SARS-CoV-2 Delta VOC in Guangzhou, China. *EClinicalMedicine.* 2021;40.

46. Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in Scotland:
demographics, risk of hospital admission, and vaccine effectiveness. *The Lancet.* 2021.

47. Fisman DN, Tuite AR. Evaluation of the relative virulence of novel SARS-CoV-2 variants: a
retrospective cohort study in Ontario, Canada. *Canadian Medical Association Journal.*
2021;193(42):E1619.

48. Nyberg T, Twohig KA, Harris RJ, et al. Risk of hospital admission for patients with SARS-
CoV-2 variant B.1.1.7: cohort analysis. *BMJ.* 2021;373:n1412.

49. Twohig KA, Nyberg T, Zaidi A, et al. Hospital admission and emergency care attendance
risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern:
a cohort study. *The Lancet Infectious Diseases.* 2021.

50. Graham MS, Sudre CH, May A, et al. Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. *The Lancet Public Health.* 2021;6(5):e335-e345.

51. Global Times. China approves emergency use of Sinovac's COVID-19 vaccine for children aged 3-17. 2021; https://www.globaltimes.cn/page/202106/1225430.shtml. Accessed 2021-08-22, 2021.

52. Global Times. China approves emergency use of Sinopharm COVID-19 vaccine for children aged 3-17. 2021; https://www.globaltimes.cn/page/202108/1231842.shtml. Accessed 2021-08-22, 2021.

53. Virginia Department of Health. COVID-19 Attack Rates by Vaccination Status and Age. 2021; https://www.vdh.virginia.gov/coronavirus/2021/08/23/covid-19-attack-rates-by-vaccination-status-and-age/. Accessed 2021-09-07, 2021.

54. Li L, Liu Y, Wu P, et al. Influenza-associated excess respiratory mortality in China, 2010–15: a population-based study. *The Lancet Public Health.* 2019;4(9):e473-e481.

55. Zhang J, Litvinova M, Liang Y, et al. The impact of relaxing interventions on human contact patterns and SARS-CoV-2 transmission in China. *Science Advances.* 2021;7(19):eabe2584.

56. Bosetti P, Kiem CT, Andronico A, et al. Epidemiology and control of SARS-CoV-2 epidemics in partially vaccinated populations: a modeling study applied to France. *HAL.* 2021.

57. Rosenberg ES, Holtgrave DR, Dorabawila V, et al. New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021. *MMWR.* 2021.

58. Dyson L, Hill EM, Moore S, et al. Possible future waves of SARS-CoV-2 infection generated by variants of concern with a range of characteristics. *Nature Communications.* 2021;12(1):5730.

59. Walvax Biotechnology Co. L. A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above. 2021; https://clinicaltrials.gov/ct2/show/NCT04847102. Accessed 2021-08-22, 2021.

60. Global Times. Chinese producers quickly progressing on Delta variant vaccines, ready for clinical trials. 2021; https://www.globaltimes.cn/page/202108/1230741.shtml. Accessed 2021-08-25, 2021.

61. He C, Yang J, He X, et al. A bivalent recombinant vaccine targeting the S1 protein induces neutralizing antibodies against both SARS-CoV-2 variants and wild-type of the virus. *MedComm.* 2021;2(3):430– 441.

62. Wang J. A bivalent recombinant vaccine: a promising strategy against both SARS-CoV-2 variants and wild type of the virus. *Signal Transduction and Targeted Therapy.* 2021;6(1):278.

63. Tan C-W, Chia W-N, Young BE, et al. Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors. *New England Journal of Medicine.* 2021.

64. Pan H, Wu Q, Zeng G, et al. Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial. *medRxiv.* 2021:2021.2007.2023.21261026.

619   65.   Li M, Yang J, Wang L, et al. A booster dose is immunogenic and will be needed for older
620   adults who have completed two doses vaccination with CoronaVac: a randomised,
621   double-blind, placebo-controlled, phase 1/2 clinical trial. *medRxiv.*
622   2021:2021.2008.2003.21261544.
623   66.   Thomas SJ, Moreira ED, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-
624   19 Vaccine through 6 Months. *New England Journal of Medicine.* 2021;385(19):1761-1773.
625   67.   Ministry of Health Israel. The Ministry of Health Director General Has Approved the
626   Recommendation to Administer a Third Vaccine Doe to 50-Year-Olds and Older and to
627   Other Populations. 2021; https://www.gov.il/en/departments/news/13082021-01.
628   Accessed 2021-08-22, 2021.
629   68.   U.S. Food and Drug Administration. Joint Statement from HHS Public Health and Medical
630   Experts on COVID-19 Booster Shots. 2021; https://www.fda.gov/news-events/press-
631   announcements/joint-statement-hhs-public-health-and-medical-experts-covid-19-
632   booster-shots. Accessed 2021-08-22, 2021.
633   69.   Moghadas SM, Shoukat A, Fitzpatrick MC, et al. Projecting hospital utilization during the
634   COVID-19 outbreaks in the United States. *Proceedings of the National Academy of*
635   *Sciences.* 2020;117(16):9122.
636